Evidence check: CYP2D6 in the context of allergy

The provided context contains no information on CYP2D6 in relation to allergy. CYP2D6 is a well-studied drug-metabolizing enzyme (phase I) that influences the metabolism of many medications, including some antihistamines and corticosteroids used for allergies. However, there is no strong evidence that CYP2D6 variants directly determine allergy risk or sensitization. The association is purely pharmacogenetic: individuals with different CYP2D6 phenotypes (poor, intermediate, extensive, ultrarapid metabolizers) may experience altered drug levels, efficacy, or side effects of allergy medications. Evidence is mechanistic and supported by clinical pharmacokinetic studies, but not validated for allergy diagnosis or prevention. MyBody-X currently does not offer a specific CYP2D6 test. A CYP2D6 genetic test can aid personalized drug selection, but it does not replace standard allergy workup (skin tests, IgE). Caution: interpretation requires medical supervision, as dose adjustments are only meaningful in a clinical context. Evidence: mechanistic/unclear.